{"code":0,"message":"成功","totalNum":0,"result":{"docId":"101002026082770000196","docLibId":3,"headLine":"鼻病毒疫苗1期临床试验取得积极初步结果","productCategoryId":"c0030002,c0030015,c0030016,c0030017,c0030173,c0030322,c0030475","productCategoryName":"通稿新闻线路,海外中文专线,BL广播,中文亚太线,新媒体专线,新华社客户端,新媒体通稿线路","authors":"张家伟","authorsEn":"Zhang Jiawei","authorsId":"zhangjiawei","geographyCategoryId":"","columnCategoryId":"<100001><c0030002><c0030002011>,<100004><c0030173><c0030173028>,<100004><c0030322><c23046><c0030322206>,c0030322322,<100004><c0030475><c0030475006>,<100001><c0030015>,<100001><c0030016>,<100001><c0030017>","organizationId":"c0241000","newsCategoryId":"c0270121","content":"　　新华社伦敦8月26日电（记者张家伟）英国帝国理工学院26日发布新闻公报说，一种旨在防范鼻病毒感染的候选疫苗在1期临床试验中取得令人鼓舞的初步结果。健康志愿者对该疫苗耐受性良好，单剂接种后产生了针对3类主要鼻病毒的免疫反应。","keywords":"鼻病毒,疫苗","wordCount":497,"languageId":"zh-CN","symbol":"XxjidoC000010_20260827_CBTFN0.xml","broadcastDate":"2026-08-27 10:25:53","broadcastDateTimestamp":1787797553000,"mediaTypeId":"Text","happenPlace":"","reportPlace":"","tagKeywords":"鼻病毒,耐受性,英国帝国理工学院,安慰剂,制药企业,一家生物,26日,新闻公报,免疫反应,第二阶段,两剂接种,3种不同,呼吸系统,疾病患者,这一疫苗","photoPlateNum":"","pixelHeight":null,"pixelWidth":null,"duration":null,"guidePrice":0,"previewUrl":null,"playUrl":null,"newsCategoryIdTop":"c0270121","isBought":false,"showPercentVideo":0.5,"isOrdered":false,"isCollected":false,"isViewed":false,"isDownloaded":false,"isLiked":false,"downloadCount":null,"collectedCount":null,"viewedCount":null,"tagJson":"","notionalArea":"","internalName":"国际新闻","issuerDeptId":"","issuerDept":"国际部-发稿中心","sharelink":null,"docSource":null,"attach":[],"album":null,"ordered":false,"id":"111002026082700003172","bought":false,"collected":false,"viewed":false,"downloaded":false,"liked":false}}